| abstract |
The invention relates to new polymeric conjugates of K-252a and its derivatives of the formula (II) and their use for the preparation of a pharmaceutical composition for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a specific aspect, the invention relates to the use of new polymeric conjugates of K-252a and its derivatives in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous systems. In another preferred aspect, the invention relates to the use of polymeric conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of skin pathologies, in particular skin pathologies associated with excessive keratinocyte proliferation, in particular psoriasis. In another aspect, the invention relates to the use of polymeric conjugates for the prevention, alleviation and treatment of pain associated with NGF. More specifically, the present invention relates to a polymer conjugate of K-252a and its derivatives of formula (II) when the polymer is polyethylene glycol or methoxy polyethylene glycol. |